

David Cornlath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8503277/publications.pdf>

Version: 2024-02-01

75
papers

7,064
citations

117625
34
h-index

82547
72
g-index

78
all docs

78
docs citations

78
times ranked

4153
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of current diagnostic criteria for Guillain-Barré syndrome. <i>Annals of Neurology</i> , 1990, 27, S21-S24.	5.3	1,731
2	Diagnosis and management of Guillain-Barré syndrome in ten steps. <i>Nature Reviews Neurology</i> , 2019, 15, 671-683.	10.1	463
3	The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. <i>Annals of Neurology</i> , 1994, 36, 244-246.	5.3	382
4	Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. <i>Annals of Neurology</i> , 1987, 21, 32-40.	5.3	373
5	Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. <i>Annals of Neurology</i> , 1994, 35, 304-311.	5.3	334
6	Wallerian degeneration in human nerves: Serial electrophysiological studies. <i>Muscle and Nerve</i> , 1992, 15, 687-693.	2.2	207
7	Multifocal motor neuropathy: Response to human immune globulin. <i>Annals of Neurology</i> , 1993, 33, 237-242.	5.3	193
8	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2018, 17, 35-46.	10.2	193
9	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190
10	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 242-268.	3.1	176
11	Motor conduction studies in guillain-barré syndrome: Description and prognostic value. <i>Annals of Neurology</i> , 1988, 23, 354-359.	5.3	171
12	Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. <i>Annals of Neurology</i> , 1988, 23, S34-S37.	5.3	156
13	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>European Journal of Neurology</i> , 2021, 28, 3556-3583.	3.3	153
14	Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. <i>Nature Genetics</i> , 1992, 2, 148-152.	21.4	140
15	Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Lancet Neurology</i> , 2019, 18, 784-794.	10.2	136
16	Multifocal motor neuropathy: Electrodiagnostic features. <i>Muscle and Nerve</i> , 1994, 17, 198-205.	2.2	126
17	Assessment of thoracic paraspinal muscles in the diagnosis of ALS. <i>Muscle and Nerve</i> , 1988, 11, 484-492.	2.2	102
18	Inter- and intra-examiner reliability of nerve conduction measurements in normal subjects. <i>Annals of Neurology</i> , 1991, 30, 841-843.	5.3	101

#	ARTICLE	IF	CITATIONS
19	Nerve conduction studies in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 1992, 15, 1111-1115.	2.2	97
20	Excitatory amino acids in amyotrophic lateral sclerosis: An update. <i>Annals of Neurology</i> , 1991, 30, 224-225.	5.3	95
21	Differentiating lower motor neuron syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 474-483.	1.9	93
22	Sensory nerve pathology in multifocal motor neuropathy. <i>Annals of Neurology</i> , 1996, 39, 319-325.	5.3	89
23	Changing outcome in inflammatory neuropathies. <i>Neurology</i> , 2014, 83, 2124-2132.	1.1	89
24	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	3.1	89
25	Electrophysiological studies in the Guillain-Barré syndrome: Distinguishing subtypes by published criteria. <i>Neurology</i> , 1998, 51, 1275-1279.		79
26	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. <i>Brain</i> , 2021, 144, 357-360.	7.6	77
27	Macrophage responses in inflammatory demyelinating neuropathies. <i>Annals of Neurology</i> , 1990, 27, S64-S68.	5.3	76
28	Recent advances in HIV neuropathy. <i>Current Opinion in Neurology</i> , 2006, 19, 446-450.	3.6	61
29	Paramyotonia congenita or hyperkalemic periodic paralysis? Clinical and electrophysiological features of each entity in one family. <i>Muscle and Nerve</i> , 1990, 13, 21-26.	2.2	55
30	Treatment of the neuromuscular complications of human immunodeficiency virus infection. <i>Annals of Neurology</i> , 1988, 23, S88-S91.	5.3	53
31	Conduction block in diabetic neuropathy. <i>Muscle and Nerve</i> , 1991, 14, 858-862.	2.2	43
32	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	1.9	43
33	Electrodiagnosis of human colchicine myoneuropathy. <i>Muscle and Nerve</i> , 1989, 12, 360-364.	2.2	38
34	Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MN-RS). <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 296-305.	3.1	38
35	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e590.	6.0	37
36	Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-CBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 210-215.	3.1	36

#	ARTICLE	IF	CITATIONS
37	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 113-121.	1.9	34
38	Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
39	Vestibular dysfunction in chronic inflammatory demyelinating Polyneuropathy. Annals of Neurology, 1996, 39, 529-535.	5.3	32
40	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp>: a responsiveness comparison. Journal of the Peripheral Nervous System, 2015, 20, 289-295.	3.1	30
41	The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials. Clinical Therapeutics, 2012, 34, 1056-1069.	2.5	29
42	Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. Journal of the Peripheral Nervous System, 2015, 20, 269-276.	3.1	28
43	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. Journal of the Peripheral Nervous System, 2015, 20, 277-288.	3.1	27
44	Pain in chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2017, 22, 156-161.	3.1	26
45	Disorders of neuromuscular transmission in infants and children. Muscle and Nerve, 1986, 9, 606-611.	2.2	25
46	Stimulated single-fiber electromyography in lambert-eaton myasthenic syndrome. Muscle and Nerve, 1991, 14, 1227-1230.	2.2	25
47	Rasch-transformed Total Neuropathy Score clinical version (RTNSc [®]) in patients with chemotherapy-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2015, 20, 328-332.	3.1	24
48	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials, 2016, 17, 345.	1.6	21
49	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 111-119.	3.1	20
50	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	3.1	17
51	Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity. Current Opinion in Neurology, 2019, 32, 676-683.	3.6	17
52	Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain, 2022, 145, 887-896.	7.6	16
53	Spontaneous diabetes mellitus in a rhesus monkey: Neurophysiological studies. Muscle and Nerve, 1989, 12, 233-235.	2.2	15
54	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	3.1	15

#	ARTICLE	IF	CITATIONS
55	A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 108-114.	3.1	14
56	Does ability to walk reflect general functionality in inflammatory neuropathies?. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 74-81.	3.1	13
57	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	3.1	13
58	IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. <i>Immunotherapy</i> , 2018, 10, 919-933.	2.0	10
59	Werdnig-Hoffmann disease and chronic distal spinal muscular atrophy with apparent autosomal dominant inheritance. <i>Annals of Neurology</i> , 1992, 32, 404-407.	5.3	9
60	Immunoreactive myelin basic protein in cerebrospinal fluid of patients with peripheral neuropathies. <i>Annals of Neurology</i> , 1986, 20, 370-372.	5.3	8
61	Yield of next-generation neuropathy gene panels in axonal neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 324-329.	3.1	7
62	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. <i>Clinical Neurophysiology</i> , 2022, 138, 231-240.	1.5	7
63	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1080-1088.	1.9	6
64	A novel HSPB1 mutation associated with a late onset CMT2 phenotype: Case presentation and systematic review of the literature. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 223-229.	3.1	5
65	Fatigue in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2020, 62, 649-651.	2.2	3
66	A recurrent <i>MORC2</i> mutation causes Charcot-Marie-Tooth disease type 2Z. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 184-186.	3.1	3
67	Analysis of relapse by inflammatory Rasch-built overall disability scale status in the <i>PATH</i> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 159-165.	3.1	3
68	Letter from new Editor-in-Chief. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 1-1.	3.1	1
69	Chemotherapy-induced peripheral neurotoxicity: Facts, needs and future directions. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S86-S87.	3.1	1
70	Subacute sensory neuronopathy and cancer: the identification of paraneoplastic syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 793-794.	1.9	1
71	Maybe myopathic EMG but not myopathy. <i>Clinical Neurophysiology</i> , 2021, 132, 2323.	1.5	1
72	Electrophysiological studies in the Guillain-Barré syndrome: Distinguishing subtypes by published criteria. <i>Muscle and Nerve</i> , 1998, 21, 1275-1279.	2.2	1

#	ARTICLE	IF	CITATIONS
73	Diagnosis and management of Guillain-Barré syndrome in ten steps. , 0, .		1
74	Report from the Satellite Meeting of the Peripheral Nerve Society in Sydney, Australia, July 5-7, 2010. Journal of the Peripheral Nervous System, 2010, 15, 161-163.	3.1	0
75	046...Efficacy and safety of intravenous immunoglobulin (IVIg) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A19.2-A19.	1.9	0